Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2025. The Group reported revenue growth of 7% (6% in constant currency) to $3.349 billion, compared to $3.127 billion in 2024 with growth in all three geographies, North America, MENA, and Europe. Said Darwazah, […] The post Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes appeared first on Web-Release.
Breaking News:
- Faraday Future Completes Delivery of EAI Robots in Texas, Expanding “Robot & Vehicle + Education” and “Robot & Vehicle + Performance” Scenarios
- NTT DATA unveils NVIDIA-powered enterprise AI factories to support secure AI adoption and help clients drive measurable ROI
- G-SHOCK Introduces the GA-2100K Series Inspired by the Energy of Nightlife
- Alteryx Accelerates its Next Phase of Growth with AI-Ready Data and Automation at Enterprise Scale
- Dubai Chamber of Commerce organises 35 meetings with Business Groups and Councils to support private sector resilience
- A Feast, Family & Festivities: Celebrate Eid at The Spicery from AED 99
- Faraday Future Completes Delivery of EAI Robots in Texas, Expanding “Robot & Vehicle + Education” and “Robot & Vehicle + Performance” Scenarios
- Resilience, Strategic Adaptation, and Forward Momentum
Thursday, March 12